Understanding how patients with moderate-to-severe Crohn's disease describe the spectrum of bowel urgency definitions: Results from qualitative research

被引：0
|
作者：
Dubinsky, M. C. [1 ]
Gibble, T. Hunter [2 ]
Stassek, L. [3 ]
Harding, G. [3 ]
Stefan, M. [3 ]
Fikre, T. [3 ]
Bleakman, A. Potts [4 ]
Moses, R. [4 ]
机构：
[1] Icahn Sch Med Mt Sinai, Gastroenterol, New York, NY USA
[2] Eli Lilly & Co, Value Evidence & Outcomes, Indianapolis, IN USA
[3] Evidera, Bethesda, MD USA
[4] Eli Lilly & Co, Med Affairs, Indianapolis, IN USA
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P759
引用
收藏
页码：I1405 / I1406
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial
    Panaccione, Remo
    Loftus, Edward V., Jr.
    Binion, David
    McHugh, Kevin
    Alam, Shamsul
    Chen, Naijun
    Guerette, Benoit
    Mulani, Parvez
    Chao, Jingdong
    CANADIAN JOURNAL OF GASTROENTEROLOGY, 2011, 25 (08): : 419 - 425
  • [22] Effectiveness, safety and persistence of treatment with ustekinumab in a cohort of patients with moderate-to-severe refractory Crohn's Disease
    Morales Bermudez, A. I.
    Bravo Aranda, A. M.
    Martinez Burgos, M.
    Olmedo Martin, R.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S509 - S510
  • [23] COGNITIVE DEBRIEFING OF THE SF-36V2 WITH MODERATE-TO-SEVERE CROHN'S DISEASE PATIENTS
    White, M. K.
    Yarlas, A.
    Ingham, M.
    Han, C.
    VALUE IN HEALTH, 2016, 19 (03) : A316 - A316
  • [24] Adalimumab treatment reduces extraintestinal manifestations in patients with moderate-to-severe Crohn's disease: a pooled analysis
    Louis, E. J.
    Lofberg, R.
    Reinisch, W.
    Schwartz, D.
    Maa, J-F
    Berg, S.
    Huang, B.
    Wang, A. W.
    Robinson, A. M.
    Pappalardo, B.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S351 - S352
  • [25] Risankizumab Induces Early Clinical Remission and Response in Patients With Moderate-To-Severe Crohn's Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies
    Schreiber, Stefan
    Ferrante, Marc
    Panaccione, Remo
    Colombel, Jean-Frederic
    Hisamatsu, Tadakazu
    Lim, Allen
    Lindsay, James
    Rubin, David T.
    Sandborn, William
    Neimark, Ezequiel
    Song, Alexandra
    Liao, Xiaomei
    Feng, Tian
    Berg, Sofie
    Wallace, Kori
    D'Haens, Geert
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S314 - S315
  • [26] Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
    Bossuyt, P.
    Ferrante, M.
    Baert, F.
    Danese, S.
    Feagan, B. G.
    Loftus, E. V., Jr.
    Panes, J.
    Peyrin-Biroulet, L.
    Ran, Z.
    Armuzzi, A.
    D'Haens, G. R.
    Song, A.
    Neimark, E.
    Liao, X.
    Zhou, Q.
    Berg, S.
    Wallace, K.
    Panaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S033 - S034
  • [27] Risankizumab Therapy Induces Improvements in Endoscopic Endpoints in Patients With Moderate-To-Severe Crohn's Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies
    Bossuyt, Peter
    Ferrante, Marc
    Baert, Filip
    Danese, Silvio
    Feagan, Brian
    Loftus, Edward V.
    Panes, Julian
    Peyrin-Biroulet, Laurent
    Ran, Zhihua
    Armuzzi, Alessandro
    D'Haens, Geert
    Song, Alexandra
    Neimark, Ezequiel
    Liao, Xiaomei
    Zhou, Qian
    Berg, Sofie
    Wallace, Kori
    Panaccione, Remo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S357 - S358
  • [28] Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
    Schreiber, S. W.
    Ferrante, M.
    Panaccione, R.
    Colombel, J. F.
    Hisamatsu, T.
    Lim, A.
    Lindsay, J. O.
    Rubin, D. T.
    Sandborn, W. J.
    Neimark, E.
    Song, A. P.
    Liao, X.
    Feng, T.
    Berg, S.
    Wallace, K.
    D'Haens, G. R.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S026 - S027
  • [29] Adalimumab Treatment Results in Deep Remission for Patients With Moderate to Severe Ileocolonic Crohn's Disease: Results From EXTEND
    Colombel, Jean-Frederic
    Rutgeerts, Paul J.
    Sandborn, William J.
    Camez, Anne A.
    Pollack, Paul F.
    Chen, Naijun
    Yang, Mei
    Mulani, Parvez
    Chao, Jingdong
    GASTROENTEROLOGY, 2010, 138 (05) : S518 - S518
  • [30] Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn's Disease: Results From the Phase 3b SEQUENCE Trial
    Peyrin-Biroulet, L.
    Bossuyt, P.
    Regueiro, M.
    Schreiber, S.
    Gecse, K.
    Irving, P.
    D'Haens, G.
    Cao, Q.
    Neimark, E.
    Huang, X.
    Anschutz, T.
    Kligys, K.
    O'Brien, D.
    Panaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I90 - I91
12345